Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKesson
Merck
Harvard Business School
Mallinckrodt

Last Updated: February 7, 2023

Details for Patent: 9,840,505


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,840,505 protect, and when does it expire?

Patent 9,840,505 protects COPIKTRA and is included in one NDA.

This patent has forty patent family members in twenty-three countries.

Summary for Patent: 9,840,505
Title:Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Inventor(s): Ren; Pingda (San Diego, CA), Martin; Michael (San Marcos, CA), Isbester; Paul (Castleton, NY), Lane; Benjamin S. (Lynnfield, MA), Kropp; Jason (Westford, MA)
Assignee: Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/016,117
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,840,505

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,840,505

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 084824 See Plans and Pricing
Argentina 117467 See Plans and Pricing
Australia 2012205669 See Plans and Pricing
Australia 2015258280 See Plans and Pricing
Brazil 112013017670 See Plans and Pricing
Canada 2824197 See Plans and Pricing
Chile 2013002007 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
McKinsey
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.